Table 1 The studies of bevacizumab treatment for radioactive cerebral necrosis
From: Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues
Year | Author | Cases | Diagnosis | Treatment schedule | Radiographic response (MRI) | Toxicity | follow-up time after last Bevacizumab delivery | Recurrence |
|---|---|---|---|---|---|---|---|---|
2007 | Gonzalez J et al. | 8 | MRI and biopsy | 5 mg/kg/2 weeks or 7.5 mg/kg/3 weeks schedule | reduction in all 8 patients | NA | NA | NA |
2009 | Torcuator R, et al. | 6 | biopsy | 10 mg/kg q2w × 6.8 average cycles | Radiographic response 6/6 patients (100%) | little | NA | NA |
2009 | Levin VA,et al. | 14 | MRI or/and biospy | 7.5 mg/kg q3weeks × media 4 cycles | All Patients showed improvement in neurological symptoms or signs. | 3/11 patients had serious adverse events | 10 months | 2 patients |
2013 | Furuse M, et al. | 11 | Amino Acid PET and MRI | 5 mg/kg q2weeks × 3–6 cycles | The median reduction ratio was 65.5% of flair MRI. | little | NA | The 6-month and 1-year tumor or necrosis PFS rates were 81.8 and 36.4% |
2013 | Boothe D, et al. | 14 lesions in 11 patients | MRI and PET, 2 patients had biopsy confirmed | 10 mg/kg every 2 weeks. The mean duration was 96.2 days | RN volume decreased by a mean of 64.4% | NA | NA | 7/14 patients recurrence. |
2012 | Wang Y, et al. | 17 | MRI and PET | 7.5 mg/kg q2weeks × media 4 cycles | MRI imaging reduction of 54.9 and 48.4% in post-gadolinium and T2-weighted scans, respectively | little | median 6 months (4 to12 months) | 1 patient |
2014 | Yonezawa S,et al. | 9 | MRI or MET-PET | 5 mg/kg /2 weeks × 6 cycles | response in all patients | little | NA | NA |
2015 | Sadraei NH,et al. | 24 | MRI,PET and/or biopsy | 5 or 10 mg/kg /2w, 7.5 or 15 mg/kg / 3w ×6 (2–13 cycles) | radiographic improvement in 23 of 24 patients | little | NA | NA |
2016 | Zhuang HQ,et al. | 14 | MRI,PET and/or pathology | 5 mg/kg q3weeks × at least 3 cycles | 12/14 patients MRI imaging reduction | little | median 10.0 months (1.2–38.0 months) | 10/14 patients recurrence. |
2018 | Li Y,et al. | 50 | MRI | 5 mg/kg every 2 weeks for up to 4 courses | 24.0% patients did not have an effective response, and 76.0%patients showed an effective response | NA | 6 months | NA |
2018 | Xu Y,et al. | 112 | MRI | 5 mg/kg intravenously every 2 weeks, for 4 cycles | 65.5% patients in the bevacizumab group showed response | NA | 6 months | 13 patients showed RN recurrence |